American Association for Cancer Research
10780432ccr200638-sup-237749_2_supp_6345312_qbmj9y.pdf (124.49 kB)

Supplementary Figure S3 from Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer

Download (124.49 kB)
journal contribution
posted on 2023-03-31, 21:47 authored by Neelima Vidula, Taronish Dubash, Michael S. Lawrence, Antoine Simoneau, Andrzej Niemierko, Erica Blouch, Becky Nagy, Whijae Roh, Brian Chirn, Brittany A. Reeves, Giuliana Malvarosa, Jochen Lennerz, Steven J. Isakoff, Dejan Juric, Douglas Micalizzi, Seth Wander, Laura Spring, Beverly Moy, Kristen Shannon, Jerry Younger, Richard Lanman, Mehmet Toner, A. John Iafrate, Gad Getz, Lee Zou, Leif W. Ellisen, Shyamala Maheswaran, Daniel A. Haber, Aditya Bardia

MAF of mutations detected





Plasma genotyping may identify mutations in potentially “actionable” cancer genes, such as BRCA1/2, but their clinical significance is not well-defined. We evaluated the characteristics of somatically acquired BRCA1/2 mutations in patients with metastatic breast cancer (MBC). Patients with MBC undergoing routine cell-free DNA (cfDNA) next-generation sequencing (73-gene panel) before starting a new therapy were included. Somatic BRCA1/2 mutations were classified as known germline pathogenic mutations or novel variants, and linked to clinicopathologic characteristics. The effect of the PARP inhibitor, olaparib, was assessed in vitro, using cultured circulating tumor cells (CTCs) from a patient with a somatically acquired BRCA1 mutation and a second patient with an acquired BRCA2 mutation. Among 215 patients with MBC, 29 (13.5%) had somatic cfDNA BRCA1/2 mutations [nine (4%) known germline pathogenic and rest (9%) novel variants]. Known germline pathogenic BRCA1/2 mutations were common in younger patients (P = 0.008), those with triple-negative disease (P = 0.022), and they were more likely to be protein-truncating alterations and be associated with TP53 mutations. Functional analysis of a CTC culture harboring a somatic BRCA1 mutation demonstrated high sensitivity to PARP inhibition, while another CTC culture harboring a somatic BRCA2 mutation showed no differential sensitivity. Across the entire cohort, APOBEC mutational signatures (COSMIC Signatures 2 and 13) and the “BRCA” mutational signature (COSMIC Signature 3) were present in BRCA1/2-mutant and wild-type cases, demonstrating the high mutational burden associated with advanced MBC. Somatic BRCA1/2 mutations are readily detectable in MBC by cfDNA analysis, and may be present as both known germline pathogenic and novel variants.

Usage metrics

    Clinical Cancer Research



    Ref. manager